Concepts (264)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Malaria, Vivax | 12 | 2025 | 48 | 4.940 |
Why?
|
| Plasmodium vivax | 13 | 2025 | 46 | 3.940 |
Why?
|
| CD4-Positive T-Lymphocytes | 13 | 2025 | 641 | 2.240 |
Why?
|
| Toxoplasma | 5 | 2025 | 33 | 2.000 |
Why?
|
| Cytokines | 16 | 2023 | 935 | 1.730 |
Why?
|
| Interferon-gamma | 7 | 2025 | 567 | 1.730 |
Why?
|
| Monocytes | 9 | 2021 | 353 | 1.730 |
Why?
|
| Toxoplasmosis, Ocular | 3 | 2025 | 7 | 1.680 |
Why?
|
| CD8-Positive T-Lymphocytes | 15 | 2023 | 677 | 1.430 |
Why?
|
| Toxoplasmosis | 3 | 2025 | 20 | 1.180 |
Why?
|
| Adaptive Immunity | 3 | 2025 | 100 | 1.180 |
Why?
|
| Cytotoxicity, Immunologic | 3 | 2025 | 148 | 1.070 |
Why?
|
| Malaria | 5 | 2023 | 148 | 1.050 |
Why?
|
| Reticulocytes | 3 | 2021 | 12 | 1.010 |
Why?
|
| Chagas Cardiomyopathy | 2 | 2024 | 7 | 1.000 |
Why?
|
| Asymptomatic Infections | 2 | 2025 | 29 | 0.950 |
Why?
|
| Mitochondria | 2 | 2021 | 371 | 0.910 |
Why?
|
| Chagas Disease | 4 | 2019 | 36 | 0.900 |
Why?
|
| Inflammation Mediators | 5 | 2020 | 177 | 0.830 |
Why?
|
| Immunologic Memory | 6 | 2023 | 288 | 0.810 |
Why?
|
| B-Lymphocytes | 6 | 2024 | 572 | 0.800 |
Why?
|
| Antibodies, Protozoan | 3 | 2019 | 52 | 0.800 |
Why?
|
| Lymphocyte Activation | 10 | 2024 | 758 | 0.800 |
Why?
|
| Immunity | 2 | 2019 | 107 | 0.740 |
Why?
|
| Adult | 30 | 2025 | 16826 | 0.710 |
Why?
|
| Young Adult | 18 | 2025 | 4695 | 0.710 |
Why?
|
| Trypanosoma cruzi | 6 | 2024 | 52 | 0.650 |
Why?
|
| Host-Parasite Interactions | 2 | 2019 | 58 | 0.650 |
Why?
|
| Inflammation | 5 | 2023 | 1147 | 0.640 |
Why?
|
| Immune Reconstitution Inflammatory Syndrome | 4 | 2022 | 17 | 0.630 |
Why?
|
| T-Lymphocytes | 3 | 2020 | 1007 | 0.620 |
Why?
|
| Middle Aged | 26 | 2025 | 17615 | 0.610 |
Why?
|
| Dengue | 4 | 2022 | 96 | 0.600 |
Why?
|
| Receptors, CCR5 | 1 | 2019 | 58 | 0.600 |
Why?
|
| Receptors, IgG | 3 | 2021 | 41 | 0.590 |
Why?
|
| Lipopolysaccharide Receptors | 3 | 2021 | 144 | 0.580 |
Why?
|
| Male | 35 | 2025 | 29893 | 0.570 |
Why?
|
| Chemokines | 5 | 2022 | 93 | 0.550 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 2 | 2017 | 112 | 0.540 |
Why?
|
| Cardiomyopathies | 1 | 2019 | 125 | 0.540 |
Why?
|
| Humans | 54 | 2025 | 63449 | 0.540 |
Why?
|
| Female | 35 | 2025 | 32883 | 0.540 |
Why?
|
| T-Lymphocyte Subsets | 8 | 2023 | 247 | 0.530 |
Why?
|
| Cell Movement | 1 | 2019 | 454 | 0.530 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2018 | 212 | 0.500 |
Why?
|
| Interleukin-10 | 6 | 2023 | 160 | 0.490 |
Why?
|
| Adolescent | 14 | 2023 | 6245 | 0.450 |
Why?
|
| Tuberculosis | 4 | 2022 | 295 | 0.450 |
Why?
|
| Disease Progression | 1 | 2019 | 1173 | 0.440 |
Why?
|
| Immune Tolerance | 1 | 2015 | 176 | 0.440 |
Why?
|
| Yellow Fever Vaccine | 3 | 2019 | 5 | 0.440 |
Why?
|
| Dendritic Cells | 5 | 2019 | 525 | 0.420 |
Why?
|
| Erythrocytes | 1 | 2014 | 149 | 0.420 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2015 | 287 | 0.410 |
Why?
|
| Toxoplasmosis, Congenital | 3 | 2021 | 4 | 0.400 |
Why?
|
| Host-Pathogen Interactions | 1 | 2015 | 262 | 0.390 |
Why?
|
| Immunophenotyping | 6 | 2023 | 196 | 0.390 |
Why?
|
| Dengue Virus | 4 | 2022 | 99 | 0.390 |
Why?
|
| Flow Cytometry | 8 | 2023 | 664 | 0.350 |
Why?
|
| Neutrophils | 3 | 2021 | 377 | 0.320 |
Why?
|
| Leishmaniasis, Cutaneous | 2 | 2008 | 16 | 0.320 |
Why?
|
| Aged | 13 | 2024 | 14449 | 0.310 |
Why?
|
| Plasmodium berghei | 2 | 2019 | 21 | 0.310 |
Why?
|
| Chronic Disease | 2 | 2024 | 753 | 0.300 |
Why?
|
| Yellow Fever | 2 | 2019 | 4 | 0.280 |
Why?
|
| Yellow fever virus | 2 | 2019 | 5 | 0.280 |
Why?
|
| Th1 Cells | 4 | 2025 | 173 | 0.280 |
Why?
|
| Zika Virus Infection | 2 | 2018 | 36 | 0.270 |
Why?
|
| Acute Disease | 3 | 2020 | 671 | 0.270 |
Why?
|
| Reactive Oxygen Species | 2 | 2021 | 224 | 0.270 |
Why?
|
| Antigens, Protozoan | 2 | 2019 | 56 | 0.260 |
Why?
|
| Parasitemia | 2 | 2025 | 47 | 0.250 |
Why?
|
| Interleukin-6 | 3 | 2019 | 321 | 0.240 |
Why?
|
| Cell Proliferation | 3 | 2019 | 988 | 0.240 |
Why?
|
| Immunity, Innate | 3 | 2021 | 795 | 0.240 |
Why?
|
| Receptors, CXCR3 | 3 | 2022 | 35 | 0.240 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2023 | 242 | 0.230 |
Why?
|
| Antiprotozoal Agents | 2 | 2021 | 8 | 0.220 |
Why?
|
| Antibodies, Viral | 4 | 2022 | 327 | 0.220 |
Why?
|
| Antibodies, Neutralizing | 4 | 2022 | 209 | 0.220 |
Why?
|
| Child | 7 | 2023 | 4526 | 0.210 |
Why?
|
| HIV Infections | 2 | 2022 | 969 | 0.200 |
Why?
|
| Immunoglobulin G | 2 | 2015 | 459 | 0.200 |
Why?
|
| Biomarkers | 8 | 2022 | 1408 | 0.200 |
Why?
|
| Toll-Like Receptors | 2 | 2019 | 431 | 0.190 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 3 | 2012 | 71 | 0.190 |
Why?
|
| Gene Expression | 3 | 2021 | 840 | 0.190 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 3 | 2012 | 119 | 0.190 |
Why?
|
| Healthy Aging | 1 | 2022 | 8 | 0.190 |
Why?
|
| Anopheles | 1 | 2021 | 21 | 0.180 |
Why?
|
| Glycolysis | 1 | 2021 | 56 | 0.180 |
Why?
|
| Nitric Oxide Synthase Type II | 2 | 2018 | 70 | 0.180 |
Why?
|
| Extracellular Traps | 1 | 2021 | 43 | 0.180 |
Why?
|
| Interleukin-12 Subunit p40 | 1 | 2021 | 17 | 0.180 |
Why?
|
| Phagosomes | 1 | 2021 | 54 | 0.180 |
Why?
|
| Disease Susceptibility | 2 | 2019 | 165 | 0.180 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2021 | 137 | 0.170 |
Why?
|
| Malaria Vaccines | 2 | 2019 | 37 | 0.170 |
Why?
|
| Lymphocyte Subsets | 1 | 2020 | 37 | 0.170 |
Why?
|
| Lymphocytes | 1 | 2021 | 201 | 0.170 |
Why?
|
| Mice | 11 | 2022 | 10845 | 0.170 |
Why?
|
| Bunyaviridae Infections | 1 | 2019 | 2 | 0.160 |
Why?
|
| Seroconversion | 1 | 2019 | 6 | 0.160 |
Why?
|
| Superoxide Dismutase | 1 | 2021 | 225 | 0.160 |
Why?
|
| Severity of Illness Index | 3 | 2020 | 1553 | 0.160 |
Why?
|
| Th2 Cells | 2 | 2018 | 98 | 0.160 |
Why?
|
| Thrombocytopenia | 1 | 2020 | 54 | 0.160 |
Why?
|
| Adenosine Triphosphate | 1 | 2021 | 293 | 0.160 |
Why?
|
| Malaria, Cerebral | 1 | 2019 | 22 | 0.160 |
Why?
|
| Interferon-alpha | 1 | 2019 | 103 | 0.150 |
Why?
|
| Receptors, CCR6 | 1 | 2019 | 9 | 0.150 |
Why?
|
| Animals | 14 | 2022 | 20663 | 0.150 |
Why?
|
| Receptors, CCR4 | 1 | 2018 | 4 | 0.150 |
Why?
|
| Leishmania major | 1 | 2018 | 8 | 0.150 |
Why?
|
| Amphotericin B | 1 | 2018 | 23 | 0.150 |
Why?
|
| Leishmaniasis, Visceral | 1 | 2018 | 14 | 0.150 |
Why?
|
| Brazil | 4 | 2021 | 100 | 0.140 |
Why?
|
| Mice, Inbred C57BL | 8 | 2018 | 3396 | 0.140 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 2019 | 111 | 0.140 |
Why?
|
| Zika Virus | 1 | 2018 | 35 | 0.140 |
Why?
|
| Squalene | 1 | 2017 | 1 | 0.140 |
Why?
|
| alpha-Tocopherol | 1 | 2017 | 18 | 0.130 |
Why?
|
| Interferon Type I | 2 | 2017 | 187 | 0.130 |
Why?
|
| Trigeminal Ganglion | 1 | 2017 | 4 | 0.130 |
Why?
|
| Leishmania | 2 | 2008 | 12 | 0.130 |
Why?
|
| Polysorbates | 1 | 2017 | 41 | 0.130 |
Why?
|
| Toll-Like Receptor 2 | 2 | 2017 | 222 | 0.130 |
Why?
|
| Antigens, CD1d | 1 | 2016 | 29 | 0.130 |
Why?
|
| Immunotherapy | 2 | 2019 | 255 | 0.130 |
Why?
|
| Antirheumatic Agents | 1 | 2019 | 221 | 0.130 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2017 | 90 | 0.130 |
Why?
|
| Immunity, Cellular | 1 | 2017 | 178 | 0.130 |
Why?
|
| Herpesvirus 1, Human | 1 | 2017 | 82 | 0.120 |
Why?
|
| Cross-Sectional Studies | 6 | 2021 | 2576 | 0.120 |
Why?
|
| Influenza Vaccines | 1 | 2017 | 99 | 0.120 |
Why?
|
| Interleukin-8 | 1 | 2016 | 88 | 0.120 |
Why?
|
| Phagocytosis | 2 | 2014 | 264 | 0.120 |
Why?
|
| Adjuvants, Immunologic | 1 | 2017 | 227 | 0.120 |
Why?
|
| Toll-Like Receptor 9 | 2 | 2017 | 211 | 0.120 |
Why?
|
| Granulocytes | 1 | 2015 | 71 | 0.120 |
Why?
|
| Killer Cells, Natural | 1 | 2017 | 217 | 0.120 |
Why?
|
| Mice, Knockout | 6 | 2018 | 2109 | 0.120 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2019 | 337 | 0.110 |
Why?
|
| Immunoglobulin A | 1 | 2015 | 96 | 0.110 |
Why?
|
| Cells, Cultured | 5 | 2021 | 2157 | 0.110 |
Why?
|
| CTLA-4 Antigen | 1 | 2014 | 72 | 0.110 |
Why?
|
| Life Cycle Stages | 1 | 2014 | 17 | 0.110 |
Why?
|
| Melanoma, Experimental | 1 | 2014 | 44 | 0.110 |
Why?
|
| Cancer Vaccines | 1 | 2014 | 49 | 0.110 |
Why?
|
| Antigens, Neoplasm | 1 | 2014 | 136 | 0.110 |
Why?
|
| Mycobacterium tuberculosis | 2 | 2021 | 405 | 0.110 |
Why?
|
| Case-Control Studies | 4 | 2020 | 1119 | 0.100 |
Why?
|
| Antigens, Bacterial | 1 | 2014 | 199 | 0.100 |
Why?
|
| Gene Expression Regulation | 2 | 2018 | 1617 | 0.100 |
Why?
|
| Infant | 4 | 2021 | 1645 | 0.100 |
Why?
|
| Nod2 Signaling Adaptor Protein | 1 | 2012 | 26 | 0.100 |
Why?
|
| Apoptosis | 1 | 2018 | 1079 | 0.100 |
Why?
|
| Interleukin-1 Receptor-Associated Kinases | 1 | 2012 | 34 | 0.100 |
Why?
|
| Child, Preschool | 4 | 2022 | 1990 | 0.090 |
Why?
|
| Interleukin-17 | 1 | 2012 | 94 | 0.090 |
Why?
|
| Transcription, Genetic | 1 | 2015 | 878 | 0.090 |
Why?
|
| Vaccination | 3 | 2019 | 362 | 0.090 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2020 | 615 | 0.090 |
Why?
|
| Macrophages | 1 | 2017 | 1039 | 0.090 |
Why?
|
| Time | 2 | 2021 | 30 | 0.090 |
Why?
|
| Primary Cell Culture | 2 | 2021 | 78 | 0.080 |
Why?
|
| Cell Differentiation | 3 | 2021 | 1353 | 0.080 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2012 | 491 | 0.080 |
Why?
|
| Atrial Fibrillation | 1 | 2018 | 834 | 0.080 |
Why?
|
| CD8 Antigens | 1 | 2008 | 54 | 0.070 |
Why?
|
| Membrane Proteins | 1 | 2014 | 895 | 0.070 |
Why?
|
| Healthy Volunteers | 2 | 2020 | 74 | 0.070 |
Why?
|
| GPI-Linked Proteins | 2 | 2021 | 40 | 0.070 |
Why?
|
| CD4 Antigens | 1 | 2008 | 149 | 0.070 |
Why?
|
| Granzymes | 2 | 2018 | 21 | 0.070 |
Why?
|
| Cohort Studies | 3 | 2021 | 2570 | 0.070 |
Why?
|
| Disease Models, Animal | 3 | 2019 | 2187 | 0.070 |
Why?
|
| Plasmodium chabaudi | 1 | 2007 | 29 | 0.070 |
Why?
|
| Myeloid Differentiation Factor 88 | 1 | 2007 | 204 | 0.060 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2021 | 772 | 0.060 |
Why?
|
| Leishmaniasis | 1 | 2005 | 10 | 0.060 |
Why?
|
| Norepinephrine | 1 | 2005 | 102 | 0.060 |
Why?
|
| Leukocytes | 1 | 2005 | 103 | 0.060 |
Why?
|
| Dopamine | 1 | 2005 | 106 | 0.060 |
Why?
|
| Dexamethasone | 1 | 2005 | 205 | 0.050 |
Why?
|
| Glucocorticoids | 1 | 2005 | 188 | 0.050 |
Why?
|
| Phenotype | 2 | 2021 | 1207 | 0.050 |
Why?
|
| Nucleocapsid | 1 | 2022 | 12 | 0.050 |
Why?
|
| Nucleocapsid Proteins | 1 | 2022 | 36 | 0.050 |
Why?
|
| Serum | 1 | 2022 | 27 | 0.050 |
Why?
|
| Serogroup | 1 | 2022 | 35 | 0.050 |
Why?
|
| Drug Combinations | 2 | 2017 | 165 | 0.050 |
Why?
|
| CD4-CD8 Ratio | 1 | 2021 | 16 | 0.050 |
Why?
|
| Sulfadiazine | 1 | 2021 | 2 | 0.050 |
Why?
|
| Blood | 1 | 2021 | 30 | 0.050 |
Why?
|
| Pyrimethamine | 1 | 2021 | 20 | 0.050 |
Why?
|
| Lymphopenia | 1 | 2021 | 34 | 0.050 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2022 | 113 | 0.040 |
Why?
|
| Observational Studies as Topic | 1 | 2021 | 61 | 0.040 |
Why?
|
| Interleukins | 1 | 2021 | 80 | 0.040 |
Why?
|
| Cell Adhesion Molecules | 1 | 2021 | 92 | 0.040 |
Why?
|
| Seasons | 1 | 2021 | 134 | 0.040 |
Why?
|
| Antigens, CD | 1 | 2021 | 347 | 0.040 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2021 | 122 | 0.040 |
Why?
|
| Anti-HIV Agents | 1 | 2021 | 154 | 0.040 |
Why?
|
| Interleukin-12 | 1 | 2020 | 128 | 0.040 |
Why?
|
| Interleukin-27 | 1 | 2019 | 6 | 0.040 |
Why?
|
| Interleukin-2 | 1 | 2020 | 167 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2019 | 3293 | 0.040 |
Why?
|
| Serologic Tests | 1 | 2019 | 37 | 0.040 |
Why?
|
| Serine Endopeptidases | 1 | 2020 | 84 | 0.040 |
Why?
|
| Immunization, Secondary | 1 | 2019 | 48 | 0.040 |
Why?
|
| RNA Helicases | 1 | 2020 | 94 | 0.040 |
Why?
|
| Antigens, Viral | 1 | 2020 | 137 | 0.040 |
Why?
|
| Viral Nonstructural Proteins | 1 | 2020 | 93 | 0.040 |
Why?
|
| Spleen | 2 | 2013 | 483 | 0.040 |
Why?
|
| Anti-Retroviral Agents | 1 | 2019 | 76 | 0.040 |
Why?
|
| Lymphocyte Count | 1 | 2018 | 73 | 0.040 |
Why?
|
| Signal Transduction | 2 | 2021 | 3035 | 0.040 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 2018 | 109 | 0.040 |
Why?
|
| Coinfection | 1 | 2019 | 58 | 0.040 |
Why?
|
| HLA Antigens | 1 | 2018 | 63 | 0.040 |
Why?
|
| Heart Function Tests | 1 | 2018 | 15 | 0.040 |
Why?
|
| Chemokine CXCL10 | 1 | 2018 | 56 | 0.040 |
Why?
|
| Transcriptome | 1 | 2021 | 387 | 0.030 |
Why?
|
| Radiography, Thoracic | 1 | 2018 | 117 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2021 | 1358 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2018 | 883 | 0.030 |
Why?
|
| Virus Replication | 1 | 2018 | 321 | 0.030 |
Why?
|
| Interleukin-1beta | 1 | 2017 | 265 | 0.030 |
Why?
|
| Viral Load | 1 | 2016 | 231 | 0.030 |
Why?
|
| Electrocardiography | 1 | 2018 | 554 | 0.030 |
Why?
|
| Trypanocidal Agents | 1 | 2014 | 3 | 0.030 |
Why?
|
| RNA, Viral | 1 | 2016 | 276 | 0.030 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2014 | 94 | 0.030 |
Why?
|
| Parasite Load | 1 | 2014 | 4 | 0.030 |
Why?
|
| Acute-Phase Reaction | 1 | 2013 | 18 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2014 | 265 | 0.030 |
Why?
|
| Macrophages, Peritoneal | 1 | 2013 | 77 | 0.020 |
Why?
|
| HLA-DR Antigens | 1 | 2012 | 26 | 0.020 |
Why?
|
| Adoptive Transfer | 1 | 2013 | 148 | 0.020 |
Why?
|
| G-Protein-Coupled Receptor Kinase 2 | 1 | 2012 | 5 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2014 | 702 | 0.020 |
Why?
|
| Th17 Cells | 1 | 2012 | 61 | 0.020 |
Why?
|
| Superoxides | 1 | 2012 | 71 | 0.020 |
Why?
|
| Haplotypes | 1 | 2012 | 131 | 0.020 |
Why?
|
| Chemotaxis | 1 | 2012 | 49 | 0.020 |
Why?
|
| Proteomics | 1 | 2014 | 283 | 0.020 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 2013 | 245 | 0.020 |
Why?
|
| Cell Lineage | 1 | 2012 | 270 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2014 | 1147 | 0.020 |
Why?
|
| Time Factors | 1 | 2019 | 3768 | 0.020 |
Why?
|
| Alleles | 1 | 2012 | 448 | 0.020 |
Why?
|
| Genotype | 1 | 2012 | 663 | 0.020 |
Why?
|
| Lipopolysaccharides | 1 | 2013 | 624 | 0.020 |
Why?
|
| Prognosis | 1 | 2014 | 1749 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2021 | 6659 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2019 | 5463 | 0.020 |
Why?
|
| Arginase | 1 | 2008 | 6 | 0.020 |
Why?
|
| Forecasting | 1 | 2008 | 232 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2017 | 5680 | 0.020 |
Why?
|
| Leukocyte Count | 1 | 2005 | 99 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2005 | 454 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 542 | 0.010 |
Why?
|